Background. -Central venous oxygen saturation (ScvO 2 ) provides an estimation of body oxygen consumption/delivery ratio. Its use has been suggested for monitoring treatment of patients admitted for acute decompensated heart failure (ADHF) but the optimal target value has never been clearly reported. Aims. -We aimed to address the prognostic value of ScvO 2 in ADHF requiring inotrope support. Methods. -ScvO 2 was prospectively assessed in 60 patients with ADHF requiring inotrope support (mean age 62 ± 16 years; 45 men; left ventricular ejection fraction 25 ± 7%) and was compared with major adverse cardiac events (MACE), defined as heart transplantation, cardiac assistance and death.
between ScvO 2 and cardiac output or catecholamine rate. Multivariable analysis showed that ScvO 2 at 24 hours remained an independent predictor of MACE. Using the optimal cut-off of 60% derived from receiver operating characteristic curves, MACE were observed in 81% of patients (17/21) with ScvO 2 ≤ 60% at 24 hours vs. 13% (5/39) with ScvO 2 > 60% at 24 hours. Conclusion. -In patients admitted for ADHF requiring inotrope support, ScvO 2 ≤ 60% despite optimal treatment is a marker of poor outcome and might be an indicator for considering more aggressive therapy. © 2011 Elsevier Masson SAS. All rights reserved. 
MOTS CLÉS

Background
Despite improvements in medical treatment, acute decompensated heart failure (ADHF) with cardiogenic shock remains associated with high mortality (50-80%) [1] . In clinical practice, conventional treatment includes catecholamine and intravenous diuretic support, monitored by echocardiography and clinical data. European Society of Cardiology guidelines [2] recommend the use of central venous oxygen saturation (ScvO 2 ) for monitoring these patients. ScvO 2 (i.e. the oxygen saturation from a blood sample taken from the superior vena cava) provides an estimation of the body oxygen consumption/delivery ratio. According to Fick's equation, ScvO 2 is determined by organ oxygen consumption (VO 2 ; mL/minute) and supply, which depends on arterial oxygen saturation (SaO 2 ; %), haemoglobin concentration (Hb; g/L) and cardiac output (CO): ScvO 2 = SaO 2 -(VO 2 /1.34*Hb*CO).
In patients admitted for a severe sepsis or an acute myocardial infarction, ScvO 2 correlates with CO; low ScvO 2 is associated with poor prognosis. The use of ScvO 2 appears superior to clinical markers for monitoring patients with haemodynamic instability and treatment adjusted to ScvO 2 seems to provide a better outcome. However, the impact of ScvO 2 in patients admitted for ADHF remains unclear. The purpose of this study was to address the optimal target of ScvO 2 for monitoring patients admitted for ADHF requiring inotropic support.
Methods
Population study
We prospectively included 60 consecutive patients (mean age 62 ± 16 years; 45 men) admitted from November 2008 to March 2010 to the Intensive Care Unit of Henri Mondor University Hospital for ADHF requiring inotrope support. Inotropic support was added when low CO (cardiac index less than 2.2 L/minute per meter square) or impaired left ventricular (LV) ejection fraction (< 40%) was associated with low blood pressure (BP) (systolic BP < 90 mmHg or a drop in mean BP of more than 30 mmHg) or when persistent signs of low organ perfusion or oligoanuria (< 0.5 mL/kg per hour) were reported. Patients were excluded when a palliative care decision was taken, when superior vena cava catheterization failed or when associated hypovolaemic or septic shock was suspected. Patients admitted for acute myocardial infarction were excluded. Of the 60 patients included, six had no heart failure history or known LV dysfunction and 27 (45%) had ischaemic cardiomyopathy. Admission LV ejection fraction and cardiac index averaged 25 ± 7% and 1.9 ± 0.7 L/minute per meter square (confidence interval 1.1-2.7), respectively. Current medications before hospitalization included beta-blocker therapy (70%), angiotensin-converting enzyme inhibitors (79%) and oral loop diuretics (84%). The study was approved by our local (Henry-Mondor Hospital) ethics committee and all patients gave informed consent to participate.
Catecholamine and diuretic infusion
Patients admitted for ADHF received standard care according to our local protocol, which follows current guidelines [2] . All drugs were systematically delivered through a central venous catheter positioned via the jugular or subclavian vein. Optimal positioning of the central venous catheter was confirmed using chest radiography. The catheter had to be at the junction between the superior vena cava and the right atrium. The radiological landmark used to determine the appropriate position was the carina. Intravenous loop diuretics and vasodilator drugs were first recommended before inotropic support when the mean BP was more than 65 mmHg. In patients with low BP and clinical signs of low organ perfusion or with persistent oligoanuria, dobutamine infusion was recommended at a starting rate of 5 g/kg per minute. Dobutamine was increased by 2.5 g/kg per minute to a maximum of 20 g/kg per minute, according to the physician's clinical judgement. In patients with severe haemodynamic instability or under beta-blocker therapy at admission, dobutamine was started at the rate of 20 g/kg per minute. Norepinephrine was given if the mean BP remained less than 65 mmHg. Intravenous loop diuretics were systematically delivered with a starting dose adjusted to the severity of volume overload, renal function and previous diuretic oral dose used. The diuretic rate was titrated to obtain euvolaemia assessed using clinical (right ventricular congestion reduction) and echocardiography data (vena cava dilatation and LV pressure reduction). Dobutamine infusion was decreased progressively (0.1 g/kg per minute per hour) when euvolaemia and haemodynamic stability were reached. No patient needed mechanical ventilation support and, when required, oxygen was delivered through an oxygen mask to obtain an arterial oxygen saturation greater or equal to 95%. 
Transthoracic echocardiography
Transthoracic echocardiography was systematically performed at admission and after 24 hours. CO was assessed using the conventional pulsed Doppler method positioned at the LV outflow tract. LV volumes and ejection fraction were quantified using Simpson's biplane method. Early and late diastolic filling flows were assessed using conventional pulsed Doppler. Right ventricular function was quantified by the amplitude of the tricuspid annular plane systolic excursion (TAPSE). The inferior vena cava diameter was assessed from the subcostal view by M mode during the expiration period [3, 4] .
Haemodynamic monitoring
Invasive BP monitoring was performed using a radial arterial catheter. BP and urine output were monitored every hour during the first 12 hours and every 3 hours thereafter. ScvO 2 assessment was performed by a standard gas analyser using a blood sample taken from the central venous catheter. ScvO 2 was assessed before and every 12 hours after inotropic support was initiated.
Clinical outcomes
The primary endpoint was defined by the occurrence of major adverse cardiac events (MACE) that included death, heart transplantation or cardiac assistance during the hospitalization period. Heart transplantation and cardiac assistance were indicated in eligible patients (age less than 65 years without severe comorbidity) with a maximal catecholamine dose (dobutamine 20 g/kg per minute) despite an optimal volume load or a maximal diuretic dose (furosemide 1 g/24 hours); the decision was made by an expert committee that included cardiac surgeons and cardiologists not involved in the study. The French Transplantation Agency (Agence de la Biomédecine) guidelines do not include ScvO 2 as a criterion for patient referral for heart transplantation or cardiac assistance. 
Statistical analysis
Results
Admission dobutamine and furosemide rates averaged 8.7 ± 4.3 g/kg per minute (range 3-20) and 529 ± 366 mg/24 hours, respectively. Norepinephrine was added in 23 (38%) patients with persistent low BP at the rate of 0.22 ± 0.11 g/kg per minute. Overall, CO (3.2 ± 1.3 L/minute to 3.6 ± 1.2 L/minute; p = 0.06), systolic BP and renal function improved under treatment (Tables 1 and 2 ).
Outcome
During the hospitalization period (11 ± 12 days), MACE occurred in 22 (37%) patients. No MACE occurred in the first 24 hours. Deaths from refractory heart failure occurred after 14 ± 15 days in 14 patients not eligible for cardiac assistance because of advanced age or comorbidity (72 ± 14 years). Cardiac assistance and heart transplantation were required in eight patients (46 ± 10 years, range 35-63) after 15 ± 8 days under catecholamine. In patients without MACE (n = 38), dobutamine infusion was maintained for 5 ± 4 days after admission and successfully weaned in 3 ± 3 days. At admission, patients who experienced MACE had a higher plasma concentrations of bilirubin (29 ± 20 mol/L vs. 20 ± 11 mol/L; p = 0.02) and brain natriuretic peptide (6841 ± 7856 pg/mL vs. 3663 ± 3431 pg/mL; p = 0.03). At 24 hours, hyponatraemia and plasma concentrations of bilirubin and lactate were greater in the MACE group (Table 2) . Urine output was greater (4.2 ± 1.9 L vs. 2.9 ± 1.6 L; p = 0.02) and the vena cava diameter was smaller (18 ± 6 mm vs. 22 ± 5 mm; p = 0.04) in patients who did not experience MACE. In contrast, diuretic and inotrope starting rates and cardiac index at admission (2.0 ± 0.9 L/minute/m 2 vs. 1.8 ± 0.5 L/minute/m 2 ) and at 24 hours (2.1 ± 0.7 L/minute/m 2 vs. 2.0 ± 0.6 L/minute/m 2 ) did not differ according to outcome.
Admission ScvO 2 and outcome
Admission ScvO 2 before dobutamine infusion was available in 49 (82%) patients and averaged 57 ± 13% (range 28-77; Fig. 1 ). Admission ScvO 2 ≤ 60% was observed in 57% (28/49) of patients, without difference between those with and without MACE (61% vs. 55%). Admission ScvO 2 correlated with sodium (r = 0.33; p = 0.02) and the plasma concentration of brain natriuretic peptide (r = -0.31; p = 0.02) but not with CO, haemoglobin concentration and arterial oxygen saturation.
Changes in ScvO 2 and outcome
At 24 hours, ScvO 2 increased in patients without MACE but remained unchanged in those who experienced MACE (Fig. 1) . Percentages of MACE according to ScvO 2 Figure 1 . Changes in central venous oxygen saturation (ScvO 2 ; mean ± standard error) according to outcome. MACE: major cardiac events (cardiac assistance, heart transplantation or death). * p < 0.05 versus admission; † p < 0.05 versus 24 hours; ‡ p < 0.05 versus before catecholamine weaning.
quartiles are presented in Fig. 2 . Using receiver operating characteristic curves, the optimal cut-off value for predicting MACE was 60% ( Fig. 3; Table 3 ). In patients with ScvO 2 > 60% at 24 hours (n = 39), dobutamine was safely withdrawn in 87% (34/39) within 3 ± 3 days. After dobutamine withdrawal, ScvO 2 slightly decreased (68 ± 6% vs. 65 ± 8%; p = 0.03; Fig. 1) .
In contrast, when ScvO 2 was less or equal to 60% at 24 hours (n = 21), MACE occurred in 81% (17/21) of patients. In addition, the last ScvO 2 was less or equal to 60% in 90% (19/21) of patients who experienced MACE. No difference was observed between death and cardiac assistance or heart transplantation. By multivariable analysis (Table 4) , ScvO 2, urine output and bilirubin concentration were independent predictors of MACE. Area under receiver operating characteristic curves for these variables are shown in Fig. 3 . 
Relationship between ScvO 2 and other haemodynamic variables
Patients with ScvO 2 > 60% at 24 hours had a greater urine output (4.0 ± 0.3 L vs. 3.0 ± 0.3 L; p = 0.04) and vena cava diameter reduction (-18% [-4 ± 6 mm] vs + 15% [2 ± 4 mm]; p = 0.007) than patients with ScvO 2 ≤ 60%, while Fick's equation-derived VO 2 was lower (102 ± 37 mL/minute per square meter vs. 133 ± 48 mL/minute per square meter; p = 0.02). In contrast, no difference was observed between ScvO 2 and cardiac index (2.0 ± 0.6 L/minute per square meter vs. 1.9 ± 0.7 L/minute per square meter; p = 0.1 for 24-hour ScvO 2 > 60% and ≤ 60%, respectively) or catecholamine rate (dobutamine 9.1 ± 3.9 g/kg/minute vs. 8.7 ± 4.3 g/kg per minute; p = 0.3 for 24-hour ScvO 2 > 60% and ≤ 60%, respectively). In addition, we did not observe a significant association between ScvO 2 and the TAPSE value at admission and 24 hours after treatment.
Discussion
Prognosis of ADHF with cardiogenic shock remains poor despite improvement in medical treatments. Management of patients with uncompensated heart failure and cardiogenic shock is conventionally based on the diagnosis and treatment of underlying causes and on symptomatic treatment with diuretics and inotrope support. The monitoring of these drugs relies on clinical and echocardiography data while ScvO 2 is poorly used because its assessment requires invasive catheter positioning and no study has clearly addressed its optimal target in ADHF. The present study demonstrates that an early increase in ScvO 2 > 60% at 24 hours is strongly correlated with a favourable outcome. MACE occurred mostly (81%) in patients with ScvO 2 that remained ≤ 60%, while event-free survival with successful dobutamine weaning was observed in 88% of patients with ScvO 2 > 60% at 24 hours. Importantly, changes in ScvO 2 appear to be more associated with a greater reduction in vena cava diameter and urine output (which are indirect markers of response to diuretic treatment and venous congestion) than with the increase in CO, as commonly believed. The usefulness of ScvO 2 for monitoring shock has been addressed in septic shock, with an impressive decrease in mortality with ScvO 2 -adjusted treatment [5] . The prognostic value of ScvO 2 has also been addressed in different critical haemodynamic situations [5] [6] [7] [8] [9] . In acute coronary syndromes, venous blood oxygen saturation has been used to identify patients at risk of heart failure or cardiogenic shock [9, 10] . Few studies have clearly addressed the prognostic value of ScvO 2 in ADHF, despite current guidelines recommending its use for monitoring drug therapy and studies suggesting its superior sensitivity over clinical markers [11, 12] . ScvO 2 reflects the balance between organ oxygen consumption and supply. A decrease in ScvO 2 may be observed when oxygen consumption increases or when oxygen supply is inadequate (anaemia, hypoxaemia or low CO). In cardiogenic shock, the decrease in ScvO 2 is commonly attributed to an inadequate oxygen delivery related to low CO [9] . ScvO 2 has been suggested for monitoring CO to guide catecholamine titration. However, this approach is under debate and several studies have reported a lack of correlation between ScvO 2 and CO in advanced heart failure patients [13] [14] [15] . Our results are consistent with these studies and we believe that the correlation between changes in ScvO 2 during ADHF and CO may be hidden by the oxygen consumption reduction related to a decrease in organ congestion. This hypothesis is supported by the correlation observed between changes in ScvO 2 and urine output, vena cava diameter and VO 2 reduction. However, we cannot exclude that our data may be biased by the limitation of echocardiography in the assessment of CO.
Bilirubin, which reflects the severity of venous congestion in ADHF, has been found to be strongly associated with a worse outcome in our study and by others [16] . This underlines the deleterious impact of overload, as reported by Mullens et al. [17] , who showed that cardiorenal syndrome in ADHF is not related to CO reduction, as commonly believed, but mainly to the severity of venous congestion. Consistently, indirect overload reduction markers (urine output and vena cava diameter reduction) correlated with a favourable outcome and improvement in ScvO 2 , probably through oxygen consumption reduction. This hypothesis is supported by Lautt et al., who showed that venous congestion induced by vena cava occlusion (cat model) reduces hepatic blood flow but is compensated by an increase in oxygen extraction [18] . The superiority of venous congestion reduction over CO restoration has been mainly reported in ADHF patients with preserved BP and might explain the lack of beneficial effect of dobutamine in these patients [19, 20] . In cardiogenic shock, the use of inotropic drugs cannot be avoided because of the low BP and persistent anuria despite adequate diuretic support. However, the rate and target of catecholamine infusion remain unclear. Our study demonstrates that venous congestion reduction may be more important than CO restoration and suggests that ScvO 2 should be used to monitor both catecholamine and diuretic rates in order to ensure a favourable response to diuretic and inotropic support.
Study limitations
Haemodynamic monitoring of cardiogenic shock is routinely performed by echocardiography and not by a Swan-Ganz catheter [21] . This may limit the interpretation of LV load pressure given the limited accuracy of echocardiography markers in this population [22] . However, the use of the vena cava diameter provides a fair assessment of venous congestion and right atrial pressure. In addition, despite an existing correlation, venous blood oxygen saturation from the superior vena cava and pulmonary artery may differ; these results should therefore be validated for venous oxygen saturation from pulmonary artery. Finally this study was done on a small sample of patients and its results -especially the 60% cut-off value -need to be validated in larger populations.
Conclusion
In ADHF requiring inotrope support, improvement in ScvO 2 to more than 60% at 24 hours appears to correlate with event free outcome. ScvO 2 improvement seems to be more related to vena cava diameter reduction and urine output than to CO improvement. In patients admitted for ADHF with cardiogenic shock, ScvO 2 ≤ 60% at 24 hours despite maximal doses of catecholamine and diuretic may be an indicator for the consideration of more aggressive therapeutic options.
